Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2017 (2017), Article ID 2316839, 6 pages
https://doi.org/10.1155/2017/2316839
Clinical Study

Concurrent Imatinib and Radiation Therapy for Unresectable and Symptomatic Desmoid Tumors

1Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA
2Department of Orthopaedic Surgery, Stanford University School of Medicine, Stanford, CA, USA
3Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA
4Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
5Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA

Correspondence should be addressed to Kristen N. Ganjoo

Received 5 February 2017; Revised 23 April 2017; Accepted 4 June 2017; Published 5 July 2017

Academic Editor: Valerae O. Lewis

Copyright © 2017 Everett J. Moding et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Desmoid tumors are locally aggressive fibroproliferative neoplasms that can lead to pain and dysfunction due to compression of nerves and surrounding structures. Desmoid tumors often progress through medical therapy, and there is frequently a delay of multiple months before radiation can provide symptomatic relief. To achieve more rapid symptomatic relief and tumor regression for unresectable desmoid tumors causing significant morbidity such as brachial plexus impingement with loss of extremity function, we have selectively utilized a combination of imatinib and radiation therapy. Here, we retrospectively review four patients treated with concurrent imatinib and radiation therapy. The treatment was typically tolerated with minimal toxicity though one patient developed avascular necrosis of the irradiated humeral head possibly related to the combined treatment. All the patients treated have had a partial response or stable disease on imaging. Improvement of symptoms was observed in all the treated patients with a median time to relief of 2.5 months after starting radiation therapy. Concurrent radiation and imatinib may represent a viable treatment option for unresectable and symptomatic desmoid tumors where rapid relief is needed to prevent permanent loss of function.